Alto Neuroscience, Inc. (ANRO)
About Alto Neuroscience, Inc.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$63.2M
- Total assets
- $184.7M
- Market cap
- $640.8M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $68.6M
- Operating income
- -$68.6M
- Income tax
- $0
- Net income
- -$61.4M
- EPS (basic)
- $-2.50
- EPS (diluted)
- $-2.50
Balance sheet
- Total assets
- $177.5M
- Current assets
- $169.3M
- Total liabilities
- $26.1M
- Current liabilities
- $10.0M
- Shareholders’ equity
- $151.5M
Cash flow
- Operating cash flow
- -$47.4M
- Investing cash flow
- -$2.1M
- Financing cash flow
- $135.7M
- Net cash flow
- $86.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $640.8M
- EPS (diluted)
- $-2.5
- Shares outstanding
- 23.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 2, 2024
Alto Neuroscience, Inc. (ANRO) Stock Price
- Reported a net loss of $63.2M.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Alto Neuroscience, Inc..
Write a review
News about Alto Neuroscience, Inc.
News & sentiment via Polygon.io
Alto Neuroscience, Inc.: frequently asked questions
Is Alto Neuroscience, Inc. an American company?
Alto Neuroscience, Inc. is a US-based company headquartered in Mountain View, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Alto Neuroscience, Inc. headquartered?
Alto Neuroscience, Inc. is headquartered in Mountain View, California, United States.
Is Alto Neuroscience, Inc. publicly traded?
Yes — Alto Neuroscience, Inc. is a publicly traded company. Its stock trades under the ticker symbol ANRO on the NYSE.
What does Alto Neuroscience, Inc. do?
Alto Neuroscience, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
